SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50206-013003
	Serial No.	10/654,796
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Nicholas P. Barker et al.
	Filing Date	September 3, 2003
	Group	1614
(37 C.F.R. § 1.98(b))	IDS Filed	June 23, 2004
	Customer No.	21559

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
BDH	4,647,454	03/03/87	Cymbalista			
	5,349,001	09/20/94	Greenwald et al.			
	5,359,030	10/25/94	Ekwuribe			
	5,382,657	01/17/95	Karasiewicz et al.			
	5,446,090	08/29/95	Harris			
	6,296,844	10/02/01	Takahashi			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
BDH	WO 98/16255 A2	04/23/98	PCT			
	WO 00/66137 A1	11/9/00	PCT			
	WO 02/32414 A2	04/25/02	PCT			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

BDH	Bailon et al., "Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon α 2a for the treatment of hepatitis C," *Bioconjugate Chem.* 12:195-202 (2001).
	Burgess et al., "Abnormal surface distribution of the human asialoglycoprotein receptor in cirrhosis," Hepatology 15:702-706 (1992).
	Cutrone et al., "Identification of critical residues in bovine IFNAR-1 responsible for interferon binding," *J. Biol. Chem.* 276:17140-17148 (2001).
	Dotzauer et al., "Hepatitis A virus-specific immunoglobulin A mediates infection of hepatocytes with hepatitis A virus via the asialoglycoprotein receptor," *J. Virology* 74:10950-10957 (2000).

EXAMINER	Bruce D. Hissey	DATE CONSIDERED	2/26/06

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Attorney Docket No.	50206-013003
	Serial No.	10/654,796
	Applicant	Nicholas P. Barker et al.
	Filing Date	September 3, 2003
	Group	1614
(37 C.F.R. § 1.98(b))	IDS Filed	June 23, 2004
	Customer No.	21559

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
BDH	Eisenberg et al., "Alaloglycoprotein receptor in human isolated hepatocytes from normal liver and its apparent increase in liver with histological alterations," *J. Hepatol.* 13:305-309 (1991).
	Eto et al., "Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon," *Nature Medicine* 5:577-581 (1999).
	Glue et al. "Pegylated interfereon- α 2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data," *Clinical Pharmacology & Therapeutics* 68:556-567 (2000).
	Grace et al., "Structural and biologic characterization of pegylated recombinant IFN- α 2b," *J Interferon Cytokine Res.* 21:1103-1115 (2001).
	Harvey et al., "Gonococcal lipooligosaccharide is a ligand for the asialoglycoprotein receptor on human sperm," *Mol. Microbiol.* 36:1059-1070 (2000).
	Harvey et al., "Receptor-mediated endocytosis of *Neisseria* gonorrhoeae into primary human urethral epithelial cells: The role of the asialoglycoprotein receptor," *Mol. Microbiol* 42:659-672 (2001).
	Hirose et al., "Regulation of asialoglycoprotein receptor expression in proliferative state of hepatocytes," *Biochem. Biophys. Res. Communications* 287:675-681 (2001).
	Karpusas et al., "The crystal structure of human interferon β at 2.2-A resolution," *Proc. Natl. Acad. Sci. USA* 94:11813-11818 (1997).
	Kasama et al., "Pharmacokinetics and biologic activities of human native and asialointerferon- βs," *J. Interferon Cytokine Res.* 15:407-415 (1995).
	Lee et al., "Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin," *J. Biolog. Chem.* 258:199-202 (1983).
	Mizuno et al., "Distributionof asialoglycoprotein receptor in human hepatocellular carcinoma," *Liver* 13:80-85 (1993).
	Monkarsh et al., "Positional isomers of monopegylated interferon α-2a: Isolation, characterization, and biological activity," *Anal. Biochem.* 247:434-440 (1997).
↓	Nyman et al., "Structural characterisation of N-linked and O-linked oligosaccharided derived from interferon- α 2b and interferon- α14c produced by Sendai-virus-induced human peripheral blood leukocytes," Eur. J. Biochem. 253:485-493 (1998).

EXAMINER Bruce D. Hissey	DATE CONSIDERED 2/26/06

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Attorney Docket No.	50206-013003
	Serial No.	10/654,796
	Applicant	Nicholas P. Barker et al.
	Filing Date	September 3, 2003
	Group	1614
(37 C.F.R. § 1.98(b))	IDS Filed	June 23, 2004
	Customer No.	21559

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
BDH	Pepinsky et al., "Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-β-1a with preserved in vitro bioactivity," *J. Pharmacol. Exp. Ther.* 297:1059-1066 (2001).
	Qin et al., "Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice," *Proc. Natl. Acad. Sci. USA* 95:14411-14416 (1998).
	Qin et al., "Human and mouse IFN- β gene therapy exhibits different anti-tumor mechanisms in mouse models," *Mol. Therapy* 4:356-364 (2001).
	Schering-Plough Research Institute, "Toxicologist's Review of Pegylated Interferon-α 2b (PEG-IFN, PEG-INTRON)," December 19, 2000.
	Tada et al., "Systemic IFN-β gene therapy results in long-term survival in mice with established colorectal liver metastases," *J. Clin. Invest.* 108:83-95 (2001).
	Takahashi et al., "Acute hepatitis in rats expressing human hepatitis B virus transgenes," *Proc. Natl. Acad. Sci. USA* 92:1470-1474 (1995).
	Treiber , "Systemic treatment of hepatocellular carcinoma," *Dig. Dis.* 19:311-323 (2001).
	Trere et al., "The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells," *British J. Cancer* 81:404-408 (1999).
	U.S. Food and Drug Administration, Product Approval Information: Peginterferon alfa-2b. May 28, 2002.
	Uwatoku et al., "Asialoglycoprotein receptors on rat dendritic cells: possible roles for binding with kupffer cells and ingesting virus particles," *Arch. Histol. Cytol.* 64:223-232 (2001).
✓	Wang et al., "Identification of the major positional isomer of pegylated interferon alpha-2b," *Biochem.* 39:10634-10640 (2000).

EXAMINER Bruce D. Hess	DATE CONSIDERED 2/26/06

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.